Compare Agilent Technologies Inc (A) vs Arqit Quantum Inc (ARQQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Arqit Quantum Inc — how do they compare? Agilent Technologies Inc trades at $128.2 (market cap $37.04B), while Arqit Quantum Inc trades at $19.21 (market cap $345.44M). The key difference: Agilent Technologies Inc is far larger — about 107.2× Arqit Quantum Inc's market cap, and Agilent Technologies Inc pays a 0.78% dividend while Arqit Quantum Inc pays none. Which is the better fit depends on your goals.
| A | ARQQ | |
|---|---|---|
Market Cap | $37.04B | $345.44M |
Sector | Health | Technology |
52-Week High | $157.20 | $58.27 |
52-Week Low | $110.24 | $11.78 |
Enterprise Value | $38.59B | $318.75M |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
ARQQ trades at $22.13, down 5.89% today, with a bullish technical signal supported by moving averages. The company reported $530K revenue for 2025 but significant losses of -$35.34M net income, with negative margins and high P/S ratio of 319.93. Recent news highlights quantum security contract wins and 829% YoY revenue growth in H1 FY26, suggesting potential turnaround momentum despite current financial challenges.
Outlook remains speculative with high execution risk; substantial revenue growth and government/telecom deals offer upside, but persistent losses and negative ROE (-181%) pose significant shareholder value concerns. Analyst consensus is divided with 50% buy rating, indicating cautious optimism amid financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →
